Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED FEBRUARY 2016. Refer to TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | adalimumab (Humira®) | ||
| Formulation | 40 mg solution for injection | ||
| Reference number | 1381 | ||
| Indication | Treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs |
||
| Company | AbbVie Ltd | ||
| BNF chapter | Musculoskeletal & joint diseases | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 1513 | ||
| NMG meeting date | 15/05/2013 | ||
| AWMSG meeting date | 12/06/2013 | ||
| Ratification by Welsh Government | 29/07/2013 | ||
| Date of issue | 31/07/2013 | ||
| NICE guidance | TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
||